These findings lead to the conclusion that CYLD plays a crucial negative regulatory role in psoriasis by inhibiting NF-κB-mediated neutrophil activation and NETs formation, so targeted activation of CYLD may represent a promising novel therapeutic strategy for psoriasis. This evidence concerns the gene NFKB1 and psoriasis.